Antibodies to platelet endothelial cell adhesion molecule-1 (PECAM-1) facilitate targeted drug delivery to endothelial cells by “vascular immunotargeting.” To define the targeting quantitatively, we investigated the endothelial binding of monoclonal antibodies (mAbs) to extracellular epitopes of PECAM-1. Surprisingly, we have found in human and mouse cell culture models that the endothelial binding of PECAM-directed mAbs and scFv therapeutic fusion protein is increased by co-administration of a paired mAb directed to an adjacent, yet distinct PECAM-1 epitope. This results in significant enhancement of functional activity of a PECAM-1-targeted scFv-thrombomodulin fusion protein generating therapeutic activated Protein C. The “collaborative enhancement” of mAb binding is affirmed in vivo, as manifested by enhanced pulmonary accumulation of intravenously administered radiolabeled PECAM-1 mAb when co-injected with an unlabeled paired mAb in mice. This is the first demonstration of a positive modulatory effect of endothelial binding and vascular immunotargeting provided by the simultaneous binding a paired mAb to adjacent distinct epitopes. The “collaborative enhancement” phenomenon provides a novel paradigm for optimizing the endothelial-targeted delivery of therapeutic agents.
References
[1]
Aird WC (2007) Endothelium as a therapeutic target in sepsis. Curr Drug Targets 8: 501–507.
[2]
Ogawara K, Rots MG, Kok RJ, Moorlag HE, Van Loenen AM, et al. (2004) A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15: 433–443.
[3]
Ding BS, Hong N, Murciano JC, Ganguly K, Gottstein C, et al. (2008) Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 111: 1999–2006.
[4]
Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125: 385–398.
[5]
Oh P, Li Y, Yu J, Durr E, Krasinska KM, et al. (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429: 629–635.
[6]
Muzykantov VR (2005) Biomedical aspects of targeted delivery of drugs to pulmonary endothelium. Expert Opin Drug Deliv 2: 909–926.
[7]
Newman PJ (1994) The role of PECAM-1 in vascular cell biology. Ann N Y Acad Sci 714: 165–174.
[8]
Muro S, Muzykantov VR (2005) Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 11: 2383–2401.
[9]
Sun J, Williams J, Yan HC, Amin KM, Albelda SM, et al. (1996) Platelet endothelial cell adhesion molecule-1 (PECAM-1) homophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression. J Biol Chem 271: 18561–18570.
[10]
Newton JP, Buckley CD, Jones EY, Simmons DL (1997) Residues on both faces of the first immunoglobulin fold contribute to homophilic binding sites of PECAM-1/CD31. J Biol Chem 272: 20555–20563.
[11]
Muller WA, Ratti CM, McDonnell SL, Cohn ZA (1989) A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 170: 399–414.
[12]
Fujiwara K (2006) Platelet endothelial cell adhesion molecule-1 and mechanotransduction in vascular endothelial cells. J Intern Med 259: 373–380.
[13]
Newman PJ, Newman DK (2003) Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 23: 953–964.
[14]
Muller WA, Weigl SA, Deng X, Phillips DM (1993) PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178: 449–460.
[15]
Yan HC, Baldwin HS, Sun J, Buck CA, Albelda SM, et al. (1995) Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). J Biol Chem 270: 23672–23680.
[16]
Yan HC, Pilewski JM, Zhang Q, DeLisser HM, Romer L, et al. (1995) Localization of multiple functional domains on human PECAM-1 (CD31) by monoclonal antibody epitope mapping. Cell Adhes Commun 3: 45–66.
[17]
Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, et al. (1996) Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. J Biol Chem 271: 11090–11098.
[18]
DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, et al. (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151: 671–677.
[19]
Sweitzer TD, Thomas AP, Wiewrodt R, Nakada MT, Branco F, et al. (2003) PECAM-directed immunotargeting of catalase: specific, rapid and transient protection against hydrogen peroxide. Free Radic Biol Med 34: 1035–1046.
[20]
Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, et al. (2005) Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106: 4191–4198.
[21]
Shuvaev VV, Han J, Yu KJ, Huang S, Hawkins BJ, et al. (2011) PECAM-targeted delivery of SOD inhibits endothelial inflammatory response. FASEB J 25: 348–357.
[22]
Nakada MT, Amin K, Christofidou-Solomidou M, O'Brien CD, Sun J, et al. (2000) Antibodies against the first Ig-like domain of human platelet endothelial cell adhesion molecule-1 (PECAM-1) that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment. J Immunol 164: 452–462.
[23]
Garnacho C, Albelda SM, Muzykantov VR, Muro S (2008) Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release 130: 226–233.
[24]
Atochina EN, Balyasnikova IV, Danilov SM, Granger DN, Fisher AB, et al. (1998) Immunotargeting of catalase to ACE or ICAM-1 protects perfused rat lungs against oxidative stress. Am J Physiol 275: L806–817.
[25]
Danilov SM, Gavrilyuk VD, Franke FE, Pauls K, Harshaw DW, et al. (2001) Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 280: L1335–1347.
[26]
Naperova IA, Balyasnikova IV, Schwartz DE, Watermeyer J, Sturrock ED, et al. (2008) Mapping of conformational mAb epitopes to the C domain of human angiotensin I-converting enzyme. J Proteome Res 7: 3396–3411.
[27]
Gurubhagavatula I, Amrani Y, Pratico D, Ruberg FL, Albelda SM, et al. (1998) Engagement of human PECAM-1 (CD31) on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release. J Clin Invest 101: 212–222.
[28]
DeLisser HM, Newman PJ, Albelda SM (1994) Molecular and functional aspects of PECAM-1/CD31. Immunol Today 15: 490–495.
[29]
Kaufman DA, Albelda SM, Sun J, Davies PF (2004) Role of lateral cell-cell border location and extracellular/transmembrane domains in PECAM/CD31 mechanosensation. Biochem Biophys Res Commun 320: 1076–1081.
[30]
Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T (2005) A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 12: 138–142.
[31]
Ding BS, Hong N, Christofidou-Solomidou M, Gottstein C, Albelda SM, et al. (2009) Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 180: 247–256.
Stan RV (2009) Anatomy of the Pulmonary Endothelium. In: Voelkel NF, Rounds S, editors. The Pulmonary Endothelium: Function in health and disease. Chichester, UK: John Wiley & Sons, Ltd. pp. 25–32.
[34]
Tsai CJ, del Sol A, Nussinov R (2008) Allostery: absence of a change in shape does not imply that allostery is not at play. J Mol Biol 378: 1–11.
[35]
Tsai CJ, Del Sol A, Nussinov R (2009) Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol Biosyst 5: 207–216.
[36]
Peracchi A, Mozzarelli A (2011) Exploring and exploiting allostery: Models, evolution, and drug targeting. Biochim Biophys Acta 1814: 922–933.
[37]
Aguilar RC, Retegui LA, Postel-Vinay MC, Roguin LP (1994) Allosteric effects of monoclonal antibodies on human growth hormone. Mol Cell Biochem 136: 35–42.
[38]
Diamond AG, Butcher GW, Howard JC (1984) Localized conformational changes induced in a class I major histocompatibility antigen by the binding of monoclonal antibodies. J Immunol 132: 1169–1175.
[39]
Aguilar RC, Blank VC, Retegui LA, Roguin LP (2000) Positive cooperative effects between receptors induced by an anti-human growth hormone allosteric monoclonal antibody. Life Sci 66: 1021–1031.
[40]
Kozower BD, Christofidou-Solomidou M, Sweitzer TD, Muro S, Buerk DG, et al. (2003) Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat Biotechnol 21: 392–398.
[41]
Stuttfeld E, Ballmer-Hofer K (2009) Structure and function of VEGF receptors. IUBMB Life 61: 915–922.
[42]
Aertgeerts K, Skene R, Yano J, Sang BC, Zou H, et al. (2011) Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 286: 18756–18765.
[43]
Kohlstedt K, Gershome C, Friedrich M, Muller-Esterl W, Alhenc-Gelas F, et al. (2006) Angiotensin-converting enzyme (ACE) dimerization is the initial step in the ACE inhibitor-induced ACE signaling cascade in endothelial cells. Mol Pharmacol 69: 1725–1732.
[44]
Gordon K, Balyasnikova IV, Nesterovitch AB, Schwartz DE, Sturrock ED, et al. (2010) Fine epitope mapping of monoclonal antibodies 9B9 and 3G8 to the N domain of angiotensin-converting enzyme (CD143) defines a region involved in regulating angiotensin-converting enzyme dimerization and shedding. Tissue Antigens 75: 136–150.
[45]
Garnacho C, Shuvaev V, Thomas A, McKenna L, Sun J, et al. (2008) RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1. Blood 111: 3024–3033.
[46]
Christofidou-Solomidou M, Nakada MT, Williams J, Muller WA, DeLisser HM (1997) Neutrophil platelet endothelial cell adhesion molecule-1 participates in neutrophil recruitment at inflammatory sites and is down-regulated after leukocyte extravasation. J Immunol 158: 4872–4878.
[47]
Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, et al. (1994) Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 63: 247–254.
[48]
Feistritzer C, Schuepbach RA, Mosnier LO, Bush LA, Di Cera E, et al. (2006) Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 281: 20077–20084.
[49]
Kowalska MA, Mahmud SA, Lambert MP, Poncz M, Slungaard A (2007) Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. Blood 110: 1903–1905.
[50]
Yan HC, Williams JP, Christofidou-Solomidou M, Delisser HM, Albelda SM (1996) The role of selectins and CD18 in leukotriene B4-mediated white blood cell emigration in human skin grafts transplanted on SCID mice. Cell Adhes Commun 3: 475–486.
[51]
Newman PJ, Berndt MC, Gorski J, White GC 2nd, Lyman S, et al. (1990) PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247: 1219–1222.
[52]
Gandhi NS, Coombe DR, Mancera RL (2008) Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 1. Molecular modeling studies. Biochemistry 47: 4851–4862.
[53]
Coombe DR, Stevenson SM, Kinnear BF, Gandhi NS, Mancera RL, et al. (2008) Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 2. Biochemical analyses. Biochemistry 47: 4863–4875.
[54]
Sachs UJ, Andrei-Selmer CL, Maniar A, Weiss T, Paddock C, et al. (2007) The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem 282: 23603–23612.
